Hands on Alemtuzumab-experience from clinical practice : whom and how to treat

@inproceedings{Hassoun2016HandsOA,
  title={Hands on Alemtuzumab-experience from clinical practice : whom and how to treat},
  author={Lina Hassoun and Judith Christina Eisele and Katja Thomas and Tjalf Ziemssen},
  year={2016}
}
Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unknown function which is found on B and T lymphocytes, leading to depletion followed by repopulation of these cells. The high efficacy of Alemtuzumab in controlling relapsing remitting MS has been shown in several clinical trials. This new therapy approach is associated with a specific side… CONTINUE READING
10 Citations
80 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 80 references

One Year Alemtuzumab – What have we Learned in Clinical Practice? Exchange of Experience between Experts on Treatment of Multiple Sclerosis

  • A Bayas, K Baum, A Bitsch, J Haas, K Hellwig, M Lang
  • Akt Neurol
  • 2015
Highly Influential
8 Excerpts

Monitoring of blood parameters under course-modified MS therapy: Substance-specific relevance and current recommendations for action

  • L Klotz, A Berthele, W Bruck, A Chan, P Flachenecker, R Gold
  • Nervenarzt: Springer Berlin Heidelberg;
  • 2016

Similar Papers

Loading similar papers…